Clinical trial · no report yet · Phase not applicable
TRIO
Three Fraction Radiation to Induce Immuno-Oncologic Response
- NCT03978663 ↗
- Active not recruiting
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- 7 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| Podcasts | 3 | |
| YouTube | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- Evaluating the Use of Stereotactic Radiation Therapy Prior to Neoadjuvant Chemotherapy for High-risk Breast Carcinoma (a SIGNAL Series Clinical Trial): Three Fraction Radiation to Induce Immuno-Oncologic Response (TRIO Trial)
- Phase
- Phase not applicable
- Status
- Active not recruiting
- Conditions
- High-Risk Cancer; Locally Advanced Breast Cancer
- Interventions
- Neoadjuvant radiotherapy
- Arms
- Neoadjuvant radiotherapy · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- Pathologic complete response
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Start
- Sep 2, 2020
- Primary completion
- Jul 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03978663 · updated Feb 20, 2026